Quick Answer
GT Biopharma, Inc. reported Stockholders Equity of $5.79 million for the year ending 2025.
- GT Biopharma, Inc. showed an increase of +92.9% in Stockholders Equity from 2025 to 2025.
- This data is from GT Biopharma, Inc.'s annual report (Form 10-K), filed with the SEC on March 2, 2026.
- XBRL data for this metric is available from 2010 to 2025 (20 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2014: -$29.57 million | Q1 2015: -$49.93 million | Q2 2015: -$22.90 million | Q3 2015: -$24.55 million | Q1 2016: -$20.22 million | Q2 2016: -$15.83 million | Q3 2016: -$17.21 million | Q1 2017: -$18.11 million | Q2 2017: -$20.08 million | Q3 2017: $253.72 million | Q1 2018: $252.26 million | Q2 2018: $246.06 million | Q3 2018: $13.31 million | Q1 2019: $10.02 million | Q2 2019: $8.98 million | Q3 2019: -$18.29 million | Q1 2020: -$29.50 million | Q2 2020: -$26.90 million | Q3 2020: -$29.78 million | Q1 2021: $24.02 million | Q2 2021: $36.29 million | Q3 2021: $31.88 million | Q1 2022: $17.79 million | Q2 2022: $15.44 million | Q3 2022: $15.95 million | Q1 2023: $13.05 million | Q2 2023: $11.76 million | Q3 2023: $10.01 million | Q1 2024: $5.31 million | Q2 2024: $5.51 million | Q3 2024: $2.10 million | Q1 2025: -$980.0 thousand.
- Over the full 20 years of available data (2010 to 2025), GT Biopharma, Inc.'s Stockholders Equity has grown by 205.8%.
- Historical annual values: Fiscal year 2025: $5.79 million | Fiscal year 2025: $3.00 million | Fiscal year 2025: -$25.88 million | Fiscal year 2024: -$1.67 million | Fiscal year 2023: $7.48 million | Fiscal year 2022: $11.73 million | Fiscal year 2021: $21.91 million | Fiscal year 2020: -$29.43 million | Fiscal year 2020: -$29.78 million | Fiscal year 2020: -$27.50 million | Fiscal year 2019: -$19.31 million | Fiscal year 2018: $11.37 million | Fiscal year 2017: $251.69 million | Fiscal year 2016: -$18.92 million | Fiscal year 2015: -$61.83 million | Fiscal year 2014: -$29.57 million | Fiscal year 2013: -$6.33 million | Fiscal year 2012: -$6.34 million | Fiscal year 2011: -$5.10 million | Fiscal year 2010: -$5.47 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: